Verve Therapeutics (VERV) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and technology

• Aims to transform cardiovascular disease care from chronic management to single-course gene editing treatments.

• Focuses on validated genetic targets (PCSK9, ANGPTL3, LPA) and flexible, proprietary delivery technologies, including GalNAc LNP.

• Pipeline includes both clinical and preclinical programs, with two assets in clinical trials.

• Lead indication targets heterozygous familial hypercholesterolemia, a severe and common genetic disease.

• Emphasizes unmet need due to poor adherence and persistence with current chronic therapies.

Clinical progress and data

• VERVE-102, targeting PCSK9, is in Phase I (Heart-2) with initial data expected in Q2 2025 from 10–12 patients across three dose cohorts.

• Early results show sustained LDL reduction (~60%) for 18 months after a single dose in humans.

• VERVE-201, targeting ANGPTL3, is in Phase I (Pulse-1) for refractory hypercholesterolemia, with a program update expected in the second half of 2025.

• VERVE-301, targeting LPA, has a nominated development candidate and is advancing preclinically.

• All programs use proprietary GalNAc LNP delivery, with demonstrated safety and potential for re-dosing if needed.

Market opportunity and adoption

• PCSK9 inhibitor market projected at $4–5 billion in 2024, but remains largely untapped with low patient penetration.

• Surveys show strong physician and patient openness to one-time gene editing, especially for younger patients needing decades of LDL lowering.

• Collaboration with Eli Lilly includes potential opt-in after Phase I, with shared U.S. profits and milestone payments.

• Pricing and access expected to be favorable due to low manufacturing costs and large addressable population.

• Product positioned as analogous to one-time cardiovascular procedures like bypass surgery for payer discussions.